Treatment Overview

Receiving a diagnosis of Prinzmetals variant angina can be confusing and frightening. Unlike typical angina, which occurs during physical exertion, this condition causes severe chest pain primarily while you are resting, often waking you up in the early hours of the morning. This unpredictability can create significant anxiety around sleep and daily relaxation. While the pain is caused by temporary spasms in the coronary arteries rather than permanent blockages, the symptoms are intense and require effective management to ensure peace of mind and physical safety.

Treatment is essential not only to relieve the immediate pain of a spasm but also to prevent complications such as arrhythmias or, in rare cases, a heart attack. The goal is to stabilize the blood vessels and prevent them from constricting. Because the frequency and severity of spasms vary widely from person to person, some experience them daily, while others have long periods of remission, treatment plans are highly individualized based on specific triggers and overall heart health (American Heart Association, 2023).

Overview of treatment options for Prinzmetal’s Variant Angina

The primary objective of treatment is to control and prevent coronary artery spasms. Unlike traditional heart disease, where procedures like stenting are common to open blocked arteries, Prinzmetal’s angina is primarily managed with medication.

The approach focuses on two distinct needs: stopping an attack that is already happening and taking daily measures to ensure attacks do not occur. While lifestyle changes such as quitting smoking and avoiding cold exposure are critical supportive steps, pharmacological therapy is the cornerstone of management. Doctors typically prescribe calcium channel blockers as the main preventative therapy, often supplementing with nitrates for immediate relief.

Medications used for Prinzmetal’s Variant Angina

Calcium channel blockers (CCBs) are the first-line treatment for preventing coronary spasms. Medications such as diltiazem, verapamil, amlodipine, and nifedipine are commonly prescribed. Clinical experience suggests that these drugs are highly effective for the vast majority of patients, often reducing the frequency of attacks significantly or eliminating them entirely.

For immediate relief during an acute episode, nitrates are the standard choice. Nitroglycerin, available as a sublingual tablet or spray, is used to stop pain quickly. Long-acting nitrates, such as isosorbide mononitrate, may be added to the daily regimen if calcium channel blockers alone are not enough to control symptoms.

It is important to note a key difference in treating this specific type of angina: beta-blockers, which are standard for other heart conditions, are often avoided. In some cases, they may slightly worsen the tendency for blood vessels to spasm (Mayo Clinic, 2022).

How these medications work

Calcium channel blockers work by targeting the muscle cells within the arterial walls. For muscles to contract, calcium must enter the cells. These medications block that entry, effectively preventing the coronary arteries from clamping down or spasming. By keeping the arteries relaxed and open, blood flow to the heart remains consistent even during rest.

Nitrates work through a different mechanism involving nitric oxide. When taken, they are converted into nitric oxide, a chemical that signals smooth muscles to relax immediately. This causes rapid widening (vasodilation) of the blood vessels, relieving the constriction and restoring oxygen supply to the heart muscle almost instantly.

Side effects and safety considerations

While these medications are effective, they influence blood pressure and can cause side effects. Calcium channel blockers may cause ankle swelling (edema), constipation, or fatigue. Nitrates commonly cause sudden, throbbing headaches or flushing due to rapid blood vessel widening.

Drug interaction safety is critical. Patients on nitrates must strictly avoid erectile dysfunction medications (e.g., sildenafil), as this combination can cause a dangerous, potentially fatal blood pressure drop. Caution is also needed with over-the-counter cold medications containing pseudoephedrine, which can constrict blood vessels. Seek immediate medical care if chest pain persists after rescue medication or is accompanied by severe shortness of breath or fainting.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Heart Association. https://www.heart.org
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  4. MedlinePlus. https://medlineplus.gov

Medications for Prinzmetal's Variant Angina

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Prinzmetal's Variant Angina.

Found 1 Approved Drug for Prinzmetal's Variant Angina

Verapamil

Brand Names
Verapamil HCI, Trandolapril, Verelan

Verapamil

Brand Names
Verapamil HCI, Trandolapril, Verelan
Form: Injection, Tablet, Capsule
Method of administration: Oral, Intravenous
FDA approval date: October 01, 1986
Classification: Angiotensin Converting Enzyme Inhibitor
Verapamil hydrochloride injection, USP is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong- Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White (W-P-W) and Lown-Ganong-Levine (L-G-L) syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1.0%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole-see CONTRAINDICATIONS and WARNINGS ), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including D.C.-cardioversion capability. As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after verapamil hydrochloride injection.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances